product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
Met (25H2) Mouse mAb
catalog :
3127S
quantity :
100 ul
price :
235 USD
clonality :
monoclonal
host :
mouse
reactivity :
human, mouse, rat
application :
western blot, immunoprecipitation
more info or order :
Cell Signaling Technology product webpage
citations: 19
Published Application/Species/DilutionReference
  • western blot; human
Cen B, Xiong Y, Song J, Mahajan S, DuPont R, McEachern K, et al. The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling. Mol Cell Biol. 2014;34:2517-32 pubmed publisher
  • western blot; rat
Yi X, Li X, Zhou Y, Ren S, Wan W, Feng G, et al. Hepatocyte growth factor regulates the TGF-β1-induced proliferation, differentiation and secretory function of cardiac fibroblasts. Int J Mol Med. 2014;34:381-90 pubmed publisher
Chaudhary S, Cho M, Nguyen T, Park K, Kwon M, Lee J. A putative pH-dependent nuclear localization signal in the juxtamembrane region of c-Met. Exp Mol Med. 2014;46:e119 pubmed publisher
Tanimoto A, Yamada T, Nanjo S, Takeuchi S, Ebi H, Kita K, et al. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. Oncotarget. 2014;5:4920-8 pubmed
Nanjo S, Yamada T, Nishihara H, Takeuchi S, Sano T, Nakagawa T, et al. Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. PLoS ONE. 2013;8:e84700 pubmed publisher
Kina S, Phonaphonh T, Liang F, Kuang H, Arasaki A, Arakaki K, et al. PDGF α receptor is a mediator for Cisplatin-induced Met expression. Eur J Pharmacol. 2013;699:227-32 pubmed publisher
Zhao L, Yasumoto K, Kawashima A, Nakagawa T, Takeuchi S, Yamada T, et al. Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer. Cancer Sci. 2013;104:1640-6 pubmed publisher
Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S, Yamada T, et al. The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. Int J Cancer. 2013;133:505-13 pubmed publisher
Nadal E, Chen G, Gallegos M, Lin L, Ferrer-Torres D, Truini A, et al. Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma. Clin Cancer Res. 2013;19:6842-52 pubmed publisher
Vaidya K, Harihar S, Phadke P, Stafford L, Hurst D, Hicks D, et al. Breast cancer metastasis suppressor-1 differentially modulates growth factor signaling. J Biol Chem. 2008;283:28354-60 pubmed publisher
Li B, Torossian A, Sun Y, Du R, Dicker A, Lu B. Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing effects. Int J Radiat Oncol Biol Phys. 2012;84:e525-31 pubmed publisher
Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, et al. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis. J Thorac Oncol. 2012;7:1078-85 pubmed publisher
Greenall S, Gherardi E, Liu Z, Donoghue J, Vitali A, Li Q, et al. Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET. PLoS ONE. 2012;7:e34658 pubmed publisher
Guo A, Villen J, Kornhauser J, Lee K, Stokes M, Rikova K, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A. 2008;105:692-7 pubmed publisher
Kentsis A, Reed C, Rice K, Sanda T, Rodig S, Tholouli E, et al. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med. 2012;18:1118-22 pubmed publisher
Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K, et al. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. Lung Cancer. 2012;75:161-6 pubmed publisher
Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190-203 pubmed
Wen Q, Zhou L, Zhou C, Zhou M, Luo W, Ma L. Change in hepatocyte growth factor concentration promote mesenchymal stem cell-mediated osteogenic regeneration. J Cell Mol Med. 2012;16:1260-73 pubmed publisher
Benedettini E, Sholl L, Peyton M, Reilly J, Ware C, Davis L, et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol. 2010;177:415-23 pubmed publisher
product information
SKU :
3127S
Product-Name :
Met (25H2) Mouse mAb
Size :
100 ul
Price-(USD) :
235 USD
Species-x-Reactivity :
H, M, R, Mk
Applications :
Immunoprecipitation
Product-Category :
RTK
Shipping-Temp :
AMBIENT
Storage-Temp :
-20°C
Product-Type :
Monoclonal Antibody
MW :
145 mature Met beta-subunit. 170 pro-Met.
Host :
Mouse
Target :
Met
Primary-Protein :
Met
Alt-Names :
AUTS9,HGF receptor,HGF/SF receptor,HGFR,Hepatocyte growth factor receptor,MET,Proto-oncogene c-Met,RCCP2,SF receptor,Scatter factor receptor,Tyrosine-protein kinase Met,c-Met,met proto-oncogene (hepatocyte growth factor receptor),met proto-oncogene tyrosine kinase,oncogene MET
more info or order :
Cell Signaling Technology product webpage
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.